Kyleena™(levonorgestrel-releasing intrauterine system) in contraception: a profile of its use
K McKeage, KA Lyseng-Williamson - Drugs & Therapy Perspectives, 2017 - Springer
Kyleena™ is a levonorgestrel (LNG) intrauterine system (IUS) that releases 12 μg of LNG
daily during the first year of use (LNG-IUS 12). It is the first low-dose LNG IUS approved for …
daily during the first year of use (LNG-IUS 12). It is the first low-dose LNG IUS approved for …
Management of primary dysmenorrhea in young women with frameless LNG-IUS
D Wildemeersch, S Jandi, A Pett… - Open Access Journal of …, 2014 - Taylor & Francis
The objective of this paper is to discuss the potential advantages of intrauterine treatment
with a frameless levonorgestrel (LNG)-releasing intrauterine system (IUS) in young women …
with a frameless levonorgestrel (LNG)-releasing intrauterine system (IUS) in young women …
Contraceptive effectiveness of levonorgestrel releasing intrauterine system
A Kapur, S Kumar - Medical Journal Armed Forces India, 2008 - Elsevier
Background This study evaluated the contraceptive effectiveness of progesterone releasing
intrauterine contraceptive devices (IUCD) and compared it with the Copper T device …
intrauterine contraceptive devices (IUCD) and compared it with the Copper T device …
Reason, myths and fantasies: preliminary data and reflections about the Portuguese experience with LNG-IUS-induced hypomenorrhea
M Oliveira da Silva, MM Costa - The European Journal of …, 1999 - Taylor & Francis
Objective To evaluate the efficacy and tolerance of the levonorgestrel-releasing intrauterine
system (LNG-IUS) among Portuguese women, with particular emphasis on the implications …
system (LNG-IUS) among Portuguese women, with particular emphasis on the implications …
The Femilis® LNG-IUS: contraceptive performance–an interim analysis
D Wildemeersch, D Janssens… - The European Journal of …, 2009 - Taylor & Francis
Objective To provide an update on the experience with the Femilis® levonorgestrel-
releasing intrauterine system (LNG-IUS) used for up to five years by parous and nulliparous …
releasing intrauterine system (LNG-IUS) used for up to five years by parous and nulliparous …
A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral …
L Borgatta, KJ Buhling, S Rybowski… - The European Journal …, 2016 - Taylor & Francis
Objectives: To compare user satisfaction and adverse events (AEs) with a levonorgestrel
intrauterine system (LNG-IUS 8; average levonorgestrel release rate approximately 8 μg/24 …
intrauterine system (LNG-IUS 8; average levonorgestrel release rate approximately 8 μg/24 …
Twelve-month discontinuation rates of levonorgestrel intrauterine system 13.5 mg and subdermal etonogestrel implant in women aged 18–44: A retrospective claims …
A Law, L Liao, J Lin, A Yaldo, R Lynen - Contraception, 2018 - Elsevier
Objective To investigate the 12-month discontinuation rates of levonorgestrel intrauterine
system 13.5 mg (LNG-IUS 13.5) and subdermal etonogestrel (ENG) implant in the US. Study …
system 13.5 mg (LNG-IUS 13.5) and subdermal etonogestrel (ENG) implant in the US. Study …
Safety and efficacy of the levonorgestrel-releasing intrauterine system: recent insights
K Gemzell-Danielsson, P Inki… - Expert Review of …, 2013 - Taylor & Francis
This overview focuses on the recent developments in the safety and efficacy of the
levonorgestrel-releasing intrauterine system (LNG-IUS) on established indications, namely …
levonorgestrel-releasing intrauterine system (LNG-IUS) on established indications, namely …
Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in contraception
J Trussell, F Hassan, N Henry, J Pocoski, A Law… - Contraception, 2014 - Elsevier
Background Levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg (total content)
is a low-dose levonorgestrel intrauterine system for up to 3 years of use. This analysis …
is a low-dose levonorgestrel intrauterine system for up to 3 years of use. This analysis …
The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability
MN Beatty, PD Blumenthal - Therapeutics and Clinical Risk …, 2009 - Taylor & Francis
The levonorgestrel-releasing intrauterine system (LNG-IUS) is a safe, effective and
acceptable form of contraception used by over 150 million women worldwide. It also has a …
acceptable form of contraception used by over 150 million women worldwide. It also has a …